Search results for "Vascular endothelial growth factor A"

showing 10 items of 180 documents

Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond

2017

Cardiotoxicity induced by chemotherapeutic agents and radiotherapy is a growing problem. In recent years, an increasing number of new drugs with targeted action have been designed. These molecules, such as monoclonal antibodies and tyrosine kinase inhibitors, can cause different type of toxicities compared to traditional chemotherapy. However, they can also cause cardiac complications such as heart failure, arterial hypertension, QT interval prolongation and arrhythmias. Currently, a field of intense research is the vascular toxicity induced by new biologic drugs, particularly those which inhibit vascular endothelial growth factor (VEGF) and its receptor (VEGF-R) and other tyrosine kinases.…

Vascular Endothelial Growth Factor APathologymedicine.medical_specialtyHeart Diseasesmedicine.medical_treatmentVascular toxicity VEGF cardiotoxicity new target therapy chemotherapy radiotherapy cardio-oncologyAntineoplastic Agents030204 cardiovascular system & hematologyQT intervalCardiooncology03 medical and health scienceschemistry.chemical_compoundCardio-oncology; Cardiotoxicity; Chemotherapy; New target therapy; Radiotherapy; Vascular toxicity; VEGF; Medicine (all); Cardiology and Cardiovascular Medicine0302 clinical medicineVascularReceptorsmedicineAnimalsHumansChemotherapyEndotheliumNew target therapyChemotherapyCardiotoxicityRadiotherapybusiness.industryVascular Endothelial Growth FactorMedicine (all)Cardiooncology; Vascular toxicity; New target therapyCardio-oncology; Cardiotoxicity; Chemotherapy; New target therapy; Radiotherapy; Vascular toxicity; VEGF; Animals; Antineoplastic Agents; Cardiotoxicity; Endothelium Vascular; Heart Diseases; Humans; Reactive Oxygen Species; Receptors Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor Amedicine.diseaseVEGFCardiotoxicityVascular endothelial growth factorRadiation therapyCardio-oncologyVascular endothelial growth factor AReceptors Vascular Endothelial Growth Factorchemistry030220 oncology & carcinogenesisHeart failureCancer researchEndothelium VascularVascular toxicityReactive Oxygen SpeciesCardiology and Cardiovascular MedicinebusinessTyrosine kinaseInternational Journal of Cardiology
researchProduct

Hypoxia-stimulated expression of angiogenic growth factors in cervical cancer cells and cervical cancer-derived fibroblasts

2001

It is generally accepted that local growth of solid tumors and their ability to establish distant metastases are dependent on the formation of new blood vessels arising from preexisting ones (angiogenesis). The angiogenic response of the host is mediated by angiogenic molecules that are released from cancer and normal stroma cells, especially fibroblasts. The goal of the present study was to quantitatively compare the expression of the two most important angiogenic growth factors (VEGF, angiogenin) of cervical cancer cells (HeLa and Me-180) with that of cervical cancer-derived fibroblasts (from one tumor/patient) under defined normoxic and hypoxic conditions in vitro. The growth kinetics of…

Vascular Endothelial Growth Factor APathologymedicine.medical_specialtyStromal cellAngiogeninAngiogenesismedicine.medical_treatmentCellUterine Cervical NeoplasmsEnzyme-Linked Immunosorbent AssayEndothelial Growth FactorsHeLamedicineHumansHypoxiaLymphokinesNeovascularization PathologicbiologyVascular Endothelial Growth FactorsGrowth factorObstetrics and GynecologyRibonuclease PancreaticFibroblastsbiology.organism_classificationIn vitroGene Expression Regulation NeoplasticKineticsmedicine.anatomical_structureOncologyCell cultureCancer researchFemaleCell DivisionHeLa CellsInternational Journal of Gynecological Cancer
researchProduct

High levels of HIF-2α highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche

2007

High HIF-2alpha protein levels in the sympathetic nervous system-derived childhood tumour neuroblastoma as well as immature phenotype correlate to unfavourable outcome. Here we show that a small subset of perivascularly located, strongly HIF-2alpha-positive tumour cells (MYCN amplified) lacks expression of differentiation markers, but expresses neural crest and early sympathetic progenitor marker genes such as Notch-1, HES-1, c-Kit, dHAND, and vimentin. HIF-2alpha- and CD68-positive tumour-associated macrophages were frequently found close to the immature and HIF-2alpha-positive neuroblastoma cells and as VEGF levels are high in the perivascular niche, we hypothesize that neuroblastoma neur…

Vascular Endothelial Growth Factor APathologymedicine.medical_specialtySympathetic Nervous SystemAngiogenesisVimentinPathology and Forensic MedicineNeuroblastomaNeuroblastomaBasic Helix-Loop-Helix Transcription FactorsTumor Cells CulturedmedicineHumansMacrophageProgenitorOncogene ProteinsN-Myc Proto-Oncogene ProteinNeovascularization PathologicbiologyMacrophagesNuclear ProteinsNeural crestmedicine.diseasePhenotypeCell HypoxiaNeoplasm ProteinsNeural CrestNeoplastic Stem Cellsbiology.proteinCancer researchStem cellThe Journal of Pathology
researchProduct

Scaffold vascularization in vivo driven by primary human osteoblasts in concert with host inflammatory cells.

2011

Successful cell-based tissue engineering requires a rapid and thorough vascularization in order to ensure long-term implant survival and tissue integration. The vascularization of a scaffold is a complex process, and is modulated by the presence of transplanted cells, exogenous and endogenous signaling proteins, and the host tissue reaction, among other influencing factors. This paper presents evidence for the significance of pre-seeded osteoblasts for the in vivo vascularization of a biodegradable scaffold. Human osteoblasts, cultured on silk fibroin micronets in vitro, migrated throughout the interconnected pores of the scaffold and produced extensive bone matrix. When these constructs we…

Vascular Endothelial Growth Factor AScaffoldMaterials scienceTime FactorsAngiogenesisCellBiophysicsFibroinNeovascularization PhysiologicBioengineeringMice SCIDBiomaterialsProsthesis ImplantationMiceTissue engineeringIn vivomedicineAnimalsHumansCells CulturedInflammationOsteoblastsTissue ScaffoldsIn vitroCell biologymedicine.anatomical_structureMechanics of MaterialsGiant cellCeramics and CompositesBlood VesselsFibroinsBiomedical engineeringBiomaterials
researchProduct

The impact of the receptor binding profiles of the vascular endothelial growth factors on their angiogenic features

2013

Abstract Background Vascular endothelial growth factors (VEGFs) are potential therapeutic agents for treatment of ischemic diseases. Their angiogenic effects are mainly mediated through VEGF receptor 2 (VEGFR2). Methods Receptor binding, signaling, and biological efficacy of several VEGFR2 ligands were compared to determine their characteristics regarding angiogenic activity and vascular permeability. Results Tested VEGFR2 ligands induced receptor tyrosine phosphorylation with different efficacy depending on their binding affinities. However, the tyrosine phosphorylation pattern and the activation of the major downstream signaling pathways were comparable. The maximal angiogenic effect stim…

Vascular Endothelial Growth Factor ASwineAngiogenesisBlotting WesternBiophysicsNeovascularization PhysiologicVascular permeabilityBiologyBiochemistryCapillary Permeabilitychemistry.chemical_compoundCell MovementHuman Umbilical Vein Endothelial CellsNeuropilinAnimalsHumansImmunoprecipitationPhosphorylationReceptorMolecular BiologyAortaCells CulturedCell Proliferationta1182Tyrosine phosphorylationrespiratory systemLigand (biochemistry)Vascular Endothelial Growth Factor Receptor-2Cell biologyVascular endothelial growth factorEndothelial stem cellchemistryBiochemistrycardiovascular systemEndothelium VascularPlasmidsSignal Transductioncirculatory and respiratory physiologyBiochimica et Biophysica Acta (BBA) - General Subjects
researchProduct

Tbx1 regulates Vegfr3 and is required for lymphatic vessel development

2010

Defects in lymphangiogenesis are added to the broad clinical manifestations of DiGeorge syndrome, caused by deletion of the T box transcription factor Tbx1.

Vascular Endothelial Growth Factor ATBX1Cellular differentiationBiologyMice03 medical and health sciences0302 clinical medicinestomatognathic systemReportLymphatic vesselmedicineAnimalsHumansLymphangiogenesisEnhancerCells CulturedResearch ArticlesLymphatic Vessels030304 developmental biology0303 health sciencesABNORMAL CAROTID ARTERIES; TRANSGENIC MICE; VELOCARDIOFACIAL SYNDROME; CARDIOVASCULAR DEFECTS; LYMPHANGIOGENESIS; LYMPHEDEMA; MOUSE; RECEPTOR-3; MUTATION; SYSTEMEndothelial CellsGene Expression Regulation DevelopmentalCell DifferentiationCell BiologyEmbryo Mammalian3. Good healthLymphangiogenesisCell biologyVascular endothelial growth factor ALymphatic systemmedicine.anatomical_structureVascular endothelial growth factor Cembryonic structuresImmunologyT-Box Domain Proteins030217 neurology & neurosurgeryJournal of Cell Biology
researchProduct

Microphthalmia, persistent hyperplastic hyaloid vasculature and lens anomalies following overexpression of VEGF-A188 from the αA-crystallin promoter

2007

Purpose During growth of the embryonic eye, dose- and site-specific expression of heparin-binding growth factors is critical for the formation of an appropriate vascular supply. Overexpression of vascular endothelial growth factor-A188 (VEGF-A188), a strongly heparin-binding, endothelial-specific mitogen, leads to severe disturbance of vascular and overall ocular morphology. This study aimed to evaluate the effects of VEGF-A188 overexpression on growth of ocular tissue components. Methods Stereological and immunohistochemical methods were employed to identify the vascular profiles, ocular tissue proportions, and cell types in VEGF-A188 transgenic mice and compare them with wild-type mice. R…

Vascular Endothelial Growth Factor Agenetic structuresMyocytes Smooth MuscleCell CountMice TransgenicEyealpha-Crystallin A ChainCongenital AbnormalitiesCorneaMiceLens CrystallineAnimalsMicrophthalmosVascular DiseasesPromoter Regions GeneticHyperplasiaEndothelial CellsHypertrophyEmbryo MammalianAntigens DifferentiationImmunohistochemistryeye diseasesActinsDisease Models AnimalAnimals NewbornBlood Vesselssense organsPericytesHeparan Sulfate ProteoglycansResearch ArticleMolecular Vision
researchProduct

Comparative study assessing effects of sonic hedgehog and VEGF in a human co-culture model for bone vascularisation strategies.

2011

The morphogen sonic hedgehog (Shh) seems to mediate adult repair processes in bone regeneration and vascularisation. In this study we investigated the effects of Shh on co-cultures consisting of human primary osteoblasts and outgrowth endothelial cells in terms of angiogenic activation and vessel maturation in comparison to the treatment with the commonly used proangiogenic factor, VEGF. Both, stimulation with VEGF or Shh, leads to an increase in the formation of microvessel-like structures compared to untreated controls. In contrast to VEGF, proangiogenic effects by Shh could already be observed after 24 h of treatment. Nevertheless, after 14 days the angiogenic activity of OEC was compara…

Vascular Endothelial Growth Factor Alcsh:Diseases of the musculoskeletal systemBone Regenerationmedicine.medical_treatmentFluorescent Antibody TechniqueAngiogenesis InhibitorsPolymerase Chain ReactionneovascularisationBasement MembraneDesminchemistry.chemical_compoundTransforming Growth Factor betaReceptors Platelet-Derived Growth FactorSonic hedgehogbiologyCell biologyUp-Regulationembryonic structuresElectrophoresis Polyacrylamide GelMorphogenmedicine.medical_specialtyanimal structuressignalling moleculesCyclopamineBlotting Westernlcsh:SurgeryNeovascularization PhysiologicEnzyme-Linked Immunosorbent AssayBone and BonesDownregulation and upregulationInternal medicinemedicineAngiopoietin-1HumansHedgehog ProteinsBone regenerationOsteoblastsGrowth factorEndothelial Cellslcsh:RD1-811bone repairco-cultureActinsCoculture TechniquesEndocrinologychemistryMyocardinbiology.proteinDesminlcsh:RC925-935AngiopoietinsEuropean cellsmaterials
researchProduct

Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules

2011

The treatment of solid malignancies includes various target drugs, such as monoclonal antibodies and tyrosine kinase inhibitors, which exert their effect alone or in combination with chemotherapy. The main part of these molecules have a target on proteins of EGFR and VEGF pathways. The particular toxicity profile and the financial impact, deriving from the application of these agents in cancer treatment, prompted a lot of researches to define predictive factors of their efficacy. Various biomarker were identified among the components of the targeted pathways. However just few studies allowed to identify specific factors to predict the toxicity of these drugs. In this review EGFR and VEGF-re…

Vascular Endothelial Growth Factor Amedicine.drug_classSettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical BiochemistryAngiogenesis InhibitorsAntineoplastic AgentsPharmacologyMonoclonal antibodyTargeted therapyAntineoplastic AgentNeoplasmsProtein-Tyrosine KinasemedicineHumansAngiogenesis Inhibitors; Antibodies Monoclonal; Antineoplastic Agents; Humans; Neoplasms; Protein-Tyrosine Kinases; Receptor Epidermal Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor ATarget therapyPharmacologyAnti vegfChemotherapybusiness.industryAntibodies MonoclonalProtein-Tyrosine KinasesErbB ReceptorsTreatment OutcomeToxicityCancer researchBiomarker (medicine)NeoplasmReceptor Epidermal Growth FactorbusinessTyrosine kinaseAngiogenesis InhibitorHuman
researchProduct

Real-life patient journey in neovascular age-related macular degeneration: a narrative medicine analysis in the Italian setting

2021

Objectives To investigate the real-life experience of patients affected by neovascular age-related macular degeneration (nAMD), in the healthcare pathway for the management of the disease, using a "patient journey" and narrative method approach. Methods The patient journey of subjects affected by nAMD was designed using a process-mapping methodology involving a team from 11 Italian centres. Subsequently, narratives were collected from nAMD patients and family members. The interviews were analyzed using the narrative medicine methodology. Results Eleven specialized retina centres across Italy were involved and 205 narratives collected. In 29% of cases, patients underestimated their symptoms …

Vascular Endothelial Growth Factor Amedicine.medical_specialtyActivities of daily livingage related macular degenerationMEDLINEAngiogenesis InhibitorsDiseaseArticle03 medical and health sciencesMacular Degeneration0302 clinical medicineMultidisciplinary approachRanibizumabHealth carereal lifeMedicinepatient journeyHumansNarrativeeducationNarrative medicineeducation.field_of_studyNarrative medicine wet AMDbusiness.industrySettore MED/30 - Malattie Apparato VisivoNarrative MedicineMacular degenerationmedicine.diseaseOphthalmologyFamily medicineIntravitreal Injections030221 ophthalmology & optometryQuality of LifeWet Macular Degenerationbusiness030217 neurology & neurosurgery
researchProduct